Suppression of STN1 enhances the cytotoxicity of chemotherapeutic agents in cancer cells by elevating DNA damage

Oncology Letters

Volumn 12, Issue 2, 2016, Pages 800-808

  Zhou, Qing ^a   Chai, Weihang ^a,b  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Chemosensitization; DNA damage; Genome stability; STN1

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CAMPTOTHECIN; ETOPOSIDE; MESO TETRA PORPHINE TETRA TOSYLATE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION ASSAY; CHEMOSENSITIVITY; COLONY FORMATION ASSAY; CYTOTOXICITY; DNA DAMAGE; DNA REPLICATION; DRUG RESISTANCE; GENE REPRESSION; GENOMIC INSTABILITY; HUMAN; IC50; STN1 GENE SUPPRESSION;

EID: 84977160017     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2016.4676     Document Type: Article

References (45)

1. Cheung-Ong K, Giaever G and Nislow C: DNA-damaging agents in cancer chemotherapy: Serendipity and chemical biology. Chem Biol 20: 648-659, 2013.
2. Lord CJ and Ashworth A: The DNA damage response and cancer therapy. Nature 481: 287-294, 2012.
3. Bouwman P and Jonkers J: The effects of deregulated DNA damage signaling on cancer chemotherapy response and resistance. Nat Rev Cancer 12: 587-598, 2012.
4. Luo Y and Leverson JD: New opportunities in chemosensitization and radiosensitization: Modulating the DNA-damage response. Expert Rev Anticancer Ther 5: 333-342, 2005.
5. Holohan C, Van Schaeybroeck S, Longley DB and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat Rev Cancer 13: 714-727, 2013.
6. Coley HM: Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev 34: 378-390, 2008.
7. Zhou BB and Bartek J: Targeting the checkpoint kinases: Chemosensitization versus chemoprotection. Nat Rev Cancer 4: 216-225, 2004.
8. Gu P, Min JN, Wang Y, Huang C, Peng T, Chai W and Chang S: CTC1 deletion results in defective telomere replication, leading to catastrophic telomere loss and stem cell exhaustion. EMBO J 31: 2309-2321, 2012.
9. Huang C, Dai X and Chai W: Human Stn1 protects telomere integrity by promoting efficient lagging-strand synthesis at telomeres and mediating C-strand fill-in. Cell Res 22: 1681-1695, 2012.
10. Stewart JA, Wang F, Chaiken MF, Kasbek C, Chastain PD II, Wright WE and Price CM: Human CST promotes telomere duplex replication and general replication restart after fork stalling. EMBO J 31: 3537-3549, 2012.
11. Casteel DE, Zhuang S, Zeng Y, Perrino FW, Boss GR, Goulian M and Pilz RB: A DNA polymerase-{alpha}{middle dot}primase cofactor with homology to replication protein A-32 regulates DNA replication in mammalian cells. J Biol Chem 284: 5807-5818, 2009.
12. Wan M, Qin J, Songyang Z and Liu D: OB-fold containing protein 1 (OBFC1), a human homolog of yeast Stn1, associates with TPP1 and is implicated in telomere length regulation. J Biol Chem 284: 26725-26731, 2009.
13. Chen LY, Majerská J and Lingner J: Molecular basis of telomere syndrome caused by CTC1 mutations. Genes Dev 27: 2099-2108, 2013.
14. Anderson BH, Kasher PR, Mayer J, Szynkiewicz M, Jenkinson EM, Bhaskar SS, Urquhart JE, Daly SB, Dickerson JE, O’Sullivan J, et al: Mutations in CTC1, encoding conserved telomere maintenance component 1, cause Coats plus. Nat Genet 44: 338-342, 2012.
15. Chen LY, Redon S and Lingner J: The human CST complex is a terminator of telomerase activity. Nature 488: 540-544, 2012.
16. Wang F, Stewart JA, Kasbek C, Zhao Y, Wright WE and Price CM: Human CST has independent functions during telomere duplex replication and C-strand fill-in. Cell Rep 2: 1096-1103, 2012.
17. Wu P, Takai H and de Lange T: Telomeric 3’ overhangs derive from resection by Exo1 and Apollo and fill-in by POT1b-associated CST. Cell 150: 39-52, 2012.
18. Shay JW and Wright WE: Telomerase therapeutics for cancer: Challenges and new directions. Nat Rev Drug Discov 5: 577-584, 2006.
19. De Cian A, Lacroix L, Douarre C, Temime-Smaali N, Trentesaux C, Riou JF and Mergny JL: Targeting telomeres and telomerase. Biochimie 90: 131-155, 2008.
20. Mondello C and Scovassi IA: Telomeres, telomerase, and apoptosis. Biochem Cell Biol 82: 498-507, 2004.
21. Chan SR and Blackburn EH: Telomeres and telomerase. Philos Trans R Soc Lond B Biol Sci 359: 109-121, 2004.
22. Liu Y, Bohr VA and Lansdorp P: Telomere, telomerase and aging. Mech Ageing Dev 129: 1-2, 2008.
23. Chen M and McLeskey SW: Telomere-based cancer treatment: emerging targeted therapies. Clin J Oncol Nursing 14: 720-727, 2010.
24. Herbert BS, Gellert GC, Hochreiter A, Pongracz K, Wright WE, Zielinska D, Chin AC, Harley CB, Shay JW and Gryaznov SM: Lipid modification of GRN163, an N3’-P5’ thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene 24: 5262-5268, 2005.
25. Dai X, Huang C, Bhusari A, Sampathi S, Schubert K and Chai W: Molecular steps of G-overhang generation at human telomeres and its function in chromosome end protection. EMBO J 29: 2788-2801, 2010.
26. Collins AR: The comet assay. Principles, applications, and limitations. Methods Mol Biol 203: 163-177, 2002.
27. Gu P and Chang S: Functional characterization of human CTC1 mutations reveals novel mechanisms responsible for the pathogenesis of the telomere disease Coats plus. Aging Cell 12: 1100-1109, 2013.
28. Pizarro JG, Folch J, Junyent F, Verdaguer E, Auladell C, Beas-Zarate C, Pallàs M and Camins A: Antiapoptotic effects of roscovitine on camptothecin-induced DNA damage in neuroblastoma cells. Apoptosis 16: 536-550, 2011.
29. Berniak K, Rybak P, Bernas T, Zarębski M, Biela E, Zhao H, Darzynkiewicz Z and Dobrucki JW: Relationship between DNA damage response, initiated by camptothecin or oxidative stress, and DNA replication, analyzed by quantitative 3D image analysis. Cytometry A 83: 913-924, 2013.
30. Nguyen TV, Chen JK and Murray V: Bleomycin DNA damage: Anomalous mobility of 3’-phosphoglycolate termini in an automated capillary DNA sequencer. J Chromatogr B Analyt Technol Biomed Life Sci 913-914: 113-122, 2013.
31. Patel JR, Dhorajiya BD, Dholakiya BZ, Badria FA and Ibrahim AS: In-vitro cytotoxicity, antioxidant, bleomycin-dependent DNA damage and immunomodulatory evaluation of 1-(4-acetylphenyl)-3-aryloxypyrrolidine-2, 5-dione based derivatives. Med Chem Res 23: 3907-3915, 2014.
32. Li X, Liu W, Wang H, Yang L, Li Y, Wen H, Ning H, Wang J, Zhang L, Li J and Fan D: Rap1 is indispensable for TRF2 function in etoposide-induced DNA damage response in gastric cancer cell line. Oncogenesis 4: e144, 2015.
33. Griaud F, Williamson AJK, Taylor S, Potier DN, Spooncer E, Pierce A and Whetton AD: BCR/ABL modulates protein phosphorylation associated with the etoposide-induced DNA damage response. J Proteomics 77: 14-26, 2012.
34. Grand CL, Han H, Muñoz RM, Weitman S, Von Hoff DD, Hurley LH and Bearss DJ: The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo. Mol Cancer Ther 1: 565-573, 2002.
35. Tarsounas M and Tijsterman M: Genomes and G-quadruplexes: For better or for worse. J Mol Biol 425: 4782-4789, 2013.
36. Bochman ML, Paeschke K and Zakian VA: DNA secondary structures: Stability and function of G-quadruplex structures. Nat Rev Genet 13: 770-780, 2012.
37. Borowicz S, Scoyk MV, Avasarala S, Karuppusamy Rathinam MK, Tauler J, Bikkavilli RK and Winn RA: The soft agar colony formation assay. J Vis Exp 92: e51998, 2014.
38. Horibata S, Vo TV, Subramanian V, Thompson PR, Coonrod SA: Utilization of the soft agar colony formation assay to identify inhibitors of tumorigenicity in breast cancer cells. J Vis Exp 99: e52727, 2015.
39. IARC/NCI/EPA Working Group: Cellular and molecular mechanisms of cell transformation and standardization of transformation assays of established cell lines for the prediction of carcinogenic chemicals: Overview and recommended protocols. Cancer Res 45: 2395-2399, 1985.
40. Kolber AR, Wong TK, Grant LD, DeWoskin RS and Hughes TJ (eds): In Vitro Toxicity Testing of Environmental Agents. Current and Future Possibilities Part A: Survey of Test Systems. Plenum Press, New York, pp321-322, 1979.
41. Pullman B, Ts’o POP and Schneider EL (eds): Interrelationship Among Aging, Cancer and Differentiation. The Jerusalem Symposia on Quantum Chemistry and Biochemistry. Volume 18. D. Reidel Publishing Company, Dordrecht, The Netherlands, pp247-248, 1985.
42. Collins AR: The comet assay for DNA damage and repair: Principles, applications, and limitations. Mol Biotechnol 26: 249-261, 2004.
43. Hosoya N and Miyagawa K: Targeting DNA damage response in cancer therapy. Cancer Sci 105: 370-388, 2014.
44. Dickerson EB, Blackburn WH, Smith MH, Kapa LB, Lyon LA and McDonald JF: Chemosensitization of cancer cells by siRNA using targeted nanogel delivery. BMC Cancer 10: 10, 2010.
45. Wang F, Stewart J and Price CM: Human CST abundance determines recovery from diverse forms of DNA damage and replication stress. Cell Cycle 13: 3488-3498, 2014.